ORCID Profile
0000-0001-7792-3450
Current Organisation
Colorado State University
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 11-08-2020
Publisher: Elsevier BV
Date: 12-2017
Publisher: MDPI AG
Date: 04-04-2022
DOI: 10.3390/PHARMACEUTICS14040790
Abstract: Injections of highly cytotoxic or immunomodulating drugs directly into the inoperable tumor is a procedure that is increasingly applied in the clinic and uses established Pt-based drugs. It is advantageous for less stable anticancer metal complexes that fail administration by the standard intravenous route. Such hydrophobic metal-containing complexes are rapidly taken up into cancer cells and cause cell death, while the release of their relatively non-toxic decomposition products into the blood has low systemic toxicity and, in some cases, may even be beneficial. This concept was recently proposed for V(V) complexes with hydrophobic organic ligands, but it can potentially be applied to other metal complexes, such as Ti(IV), Ga(III) and Ru(III) complexes, some of which were previously unsuccessful in human clinical trials when administered via intravenous injections. The potential beneficial effects include antidiabetic, neuroprotective and tissue-regenerating activities for V(V/IV) antimicrobial activities for Ga(III) and antimetastatic and potentially immunogenic activities for Ru(III). Utilizing organic ligands with limited stability under biological conditions, such as Schiff bases, further enhances the tuning of the reactivities of the metal complexes under the conditions of intratumoral injections. However, nanocarrier formulations are likely to be required for the delivery of unstable metal complexes into the tumor.
Publisher: Wiley
Date: 07-09-2020
Publisher: MDPI
Date: 29-06-2022
DOI: 10.3390/BITAP-12783
Publisher: Royal Society of Chemistry (RSC)
Date: 2019
DOI: 10.1039/C9DT00601J
Abstract: Hydrophobicity may increase the hydrolytic stability of vanadium( v ) catecholate complexes enabling rapid cellular uptake of the intact complex exhibiting potent anti-cancer activity.
Publisher: Wiley
Date: 07-09-2020
Publisher: Wiley
Date: 24-10-2023
Abstract: Two new series of complexes with pyridine‐containing Schiff bases, [VVO(SALIEP)L] and [VVO(Cl‐SALIEP)L] (SALIEP = N‐(salicylideneaminato)‐2‐(2‐aminoethylpyridine Cl‐SALIEP = N‐(5‐chlorosalicylideneaminato)‐2‐(2‐aminoethylpyridine, L = catecholato(2‐) ligand) were synthesized. Characterization by 1H and 51V NMR and UV‐Vis spectroscopies confirmed that: 1) most complexes form two major geometric isomers in solution, and [VVO(SALIEP)(DTB)] (DTB = di‐tert‐butylcatecholato(2‐)) forms two isomers that equilibrate in solution and 2) tert‐butyl substituents was necessary to stabilize the reduced V(IV) species (EPR spectroscopy and cyclic voltammetry). The pyridine moiety within the Schiff base ligands significantly changed their chemical properties with unsubstituted catecholate ligands compared with the parent HSHED (N‐(salicylideneaminato)‐Nˊ‐(2‐hydroxyethyl)‐1,2‐ethanediamine) Schiff base complexes. Immediate reduction to V(IV) occurred for the unsubstituted‐catecholato V(V) complexes on dissolution in DMSO. By contrast, the pyridine moiety within the Schiff base significantly improved the hydrolytic stability of [VVO(SALIEP)(DTB)] compared with [VVO(HSHED)(DTB)]. [VVO(SALIEP)(DTB)] had moderate stability in cell culture media. There was significant cellular uptake of the intact complex by T98g (human glioblastoma) cells and very good anti‐proliferative activity (IC50 6.7 ± 0.9 μM, 72 h), which was ~five‐fold higher compared with the non‐cancerous human cell line, HFF‐1 (IC50 34 ± 10 μM). This made it a potential drug candidate for the treatment of advanced gliomas by intracranial injections.
Publisher: Wiley
Date: 07-08-2020
Publisher: American Chemical Society (ACS)
Date: 15-12-2022
No related grants have been discovered for Debbie C. Crans.